Wedbush Reaffirms “Outperform” Rating for Werewolf Therapeutics (NASDAQ:HOWL)

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research report issued to clients and investors on Monday, RTT News reports. They currently have a $9.00 target price on the stock. Wedbush’s price target indicates a potential upside of 57.34% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. JMP Securities reiterated a “market outperform” rating and issued a $12.00 target price on shares of Werewolf Therapeutics in a research note on Monday. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research note on Monday.

Werewolf Therapeutics Stock Performance

Shares of HOWL opened at $5.72 on Monday. The firm has a market cap of $247.96 million, a price-to-earnings ratio of -5.25 and a beta of 0.71. The business’s 50 day moving average is $6.18 and its two-hundred day moving average is $4.70. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics has a 52-week low of $1.57 and a 52-week high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Thursday, March 7th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.10. Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.43%. The company had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $2.75 million. Analysts forecast that Werewolf Therapeutics will post -1.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HOWL. Financial Perspectives Inc boosted its stake in Werewolf Therapeutics by 80.0% during the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after purchasing an additional 3,000 shares in the last quarter. Certuity LLC acquired a new stake in shares of Werewolf Therapeutics in the fourth quarter valued at $39,000. Lighthouse Investment Partners LLC bought a new position in Werewolf Therapeutics during the fourth quarter valued at about $87,000. Denali Advisors LLC bought a new position in shares of Werewolf Therapeutics during the 1st quarter valued at about $172,000. Finally, PFM Health Sciences LP boosted its holdings in Werewolf Therapeutics by 35.6% during the fourth quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock worth $13,387,000 after buying an additional 909,895 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.